Avamab Pharma

Avamab Pharma is a preclinical-stage biotechnology company specializing in the development of adeno-associated virus (AAV) gene therapies for the treatment and prevention of infectious diseases. The company's proprietary Vectored Immunoprophylaxis (VIP) platform utilizes a novel, rationally engineered muscle-tropic AAV6 mutant capsid, termed AAV6.2FF, to deliver genes encoding highly potent neutralizing monoclonal antibodies (mAbs) directly in vivo. By turning the patient's own muscle cells into "bioreactors" that continuously produce and secrete protective antibodies, Avamab's approach aims to provide long-term, durable passive immunity from a single intramuscular injection. The company's pipeline includes preclinical programs targeting high-consequence pathogens and antibiotic-resistant bacteria, such as Clostridium difficile, Marburg virus, Pseudomonas aeruginosa, Staphylococcus aureus, and Respiratory Syncytial Virus (RSV).